[Special Stock] Celltrion Rises 10% on Final Approval of Rekkiro-na Sales in Europe

[Asia Economy Reporter Minji Lee] Celltrion is showing strong gains in early trading.

At 9:17 a.m. on the 15th, Celltrion was trading at 235,000 KRW, up 10% from the previous trading day. The positive impact came from the news that the European Commission (EC) granted final sales approval for the COVID-19 treatment drug Rekirona (CT-P59) in 30 European countries. Celltrion Healthcare and Celltrion Pharm, listed on the KOSDAQ market, also rose 8.3% and 14.54%, respectively.

The target users are adults (18 years and older) confirmed with COVID-19 who do not require supplemental oxygen and are at high risk of progressing to severe illness.

The company stated, "As COVID-19 cases continue to increase due to the prolonged pandemic, demand for COVID-19 treatments is expected to persist," adding, "It can contribute to normalizing the COVID-19 situation by reducing the rate at which existing patients' symptoms worsen to severe illness or death."

Earlier, on the 11th, Celltrion's stock price showed a slight rise after receiving a recommendation for sales approval of Rekirona from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA).

This content was produced with the assistance of AI translation services.